Alveolus, a leading provider of non-vascular interventional stent technology, recently received regulatory approval in the European Union (EU) on a new implantable device to be used in Non-Vascular Interventional Pulmonary Stenting.

Alveolus, having attained FDA approval in the United States earlier this year has already begun domestic commercialization. With the approval of the CE mark, Alveolus is now set to market and sell their next generation stents in the European Union (EU).

"We are pleased with the EU's approval of the Alveolus Stent Technology System (STS)," said Eric K. Mangiardi, President and CEO of Alveolus. "With the ability to market and sell our product in Europe, we are now approved in two-thirds of the global marketplace with an opportunity to leverage approval in the Pacific Rim countries. We are in active discussions with international distributors in this region and expect to sign the first definitive agreement to market the product before the end of the 4th quarter of this year."